By activating GLP-1 receptors in your body, the medication helps lower blood sugar levels and, crucially for weight management, reduces your appetite
The decision to continue, modify, or discontinue GLP-1 receptor agonist therapy should be individualised, considering the balance between therapeutic benefit and adverse effects
Looking for the full lineup of related compounds
[cited 2025 Dec 12]
According to NICE guidance (NG28), GLP-1 receptor agonists like semaglutide are recommended as second- or third-line therapy, particularly for patients with a body mass index (BMI) 35 kg/m (or lower thresholds for people of Black African, African-Caribbean, South Asian, and Chinese family origin) or those for whom insulin therapy would pose significant occupational implications
Because medications like Mounjaro and Wegovy alter how the body processes oral compounds, specialist clinical oversight is no longer optional